Lilly's Mounjaro and Zepbound post $11.7 billion quarter as Novo sales fall
Novo's fourth-quarter revenue declined 7.6% year over year with US operations down 15%, while its Wegovy pill reached roughly 50,000 weekly prescriptions.
TR
By Tom Reyes · Markets Editor
Apr 10 03:00 ETSource: 24/7 Wall St.
The wire
- 01Lilly reported $19.29 billion in fourth-quarter revenue, up 42.6%, with Mounjaro at $7.41 billion and Zepbound at $4.26 billion; Novo revenue fell 7.6% and it cut about 9,000 jobs in 2025.
- 02Novo's oral Wegovy launched in January 2026 across more than 70,000 pharmacies at a $149 monthly starter dose, while Lilly's orforglipron is submitted in the US, Japan and the EU.
- 03Watch whether orforglipron clears the FDA by mid-2026 and whether Medicare opens obesity coverage; the piece is an outlet's competitive analysis, not new clinical data.
From the source
Read at 247wallst.comEli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader
Eli Lilly and Company ( NYSE:LLY | LLY Price Prediction ) and Novo Nordisk A/S ( NYSE:NVO ) reported quarterly results in early February, and the gap between them has widened significantly. Lilly’s tirzepatide franchise is accelerating. Novo is cutting jobs, warning of a sales decline, and leaning on a newly launched pill to stabilize its position.